Management of metastatic cervical cancer: review of the literature.
This article reviews the English-language literature concerning chemotherapy for advanced, recurrent, or metastatic cervix carcinoma. Specifically, it reviews the available literature for active single agents, doublets, triplets, and multiple drug combination chemotherapy. Until recently, single-agent cisplatin was the drug of choice in metastatic cervix cancer. Various doublets, triplets, and quartlets have been reported to have higher objective response rates than single-agent cisplatin when compared in phase III clinical trials. Some have demonstrated improvements in progression-free survival, but only topotecan plus cisplatin has demonstrated an improvement in overall survival. This benefit is most apparent in patients who have a long disease-free interval from primary therapy and who have not received prior cisplatin as a radiosensitizer.
Long
Harry J
HJ
Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA. long.harry@mayo.edu
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology*; D002945:Cisplatin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008495:Medical Oncology / Q000379:methods*; D009362:Neoplasm Metastasis; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology*
D002945:Cisplatin